Patent classifications
C07D513/18
Macrocyclic LRRK2 kinase inhibitors
Compounds of Formula (I): ##STR00001## wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description.
Macrocyclic LRRK2 kinase inhibitors
Compounds of Formula (I): ##STR00001## wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description.
RAS INHIBITORS
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
RAS INHIBITORS
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Heat shock protein modulators and anti-Huntington disease therapeutic agents
Disclosed are thiadiazine compounds, derivatives and compositions thereof. The compounds, derivatives, and compositions can be used for treating or preventing a heat-shock protein responsive disorder or suppressing protein aggregation in a subject. The compounds and compositions can also be used for treating cancer, neurodegenerative disorders, and other heat-shock protein responsive disorders.
Heat shock protein modulators and anti-Huntington disease therapeutic agents
Disclosed are thiadiazine compounds, derivatives and compositions thereof. The compounds, derivatives, and compositions can be used for treating or preventing a heat-shock protein responsive disorder or suppressing protein aggregation in a subject. The compounds and compositions can also be used for treating cancer, neurodegenerative disorders, and other heat-shock protein responsive disorders.
Use of H3K9me3 modulation for enhancing cognitive function
Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
Use of H3K9me3 modulation for enhancing cognitive function
Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.